COMPASS Pathways (NASDAQ:CMPS) Releases Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• COMPASS Pathways reported a quarterly earnings per share (EPS) of ($0.38), missing analysts' estimates of ($0.37) by $0.01.
• After the earnings announcement, shares of COMPASS Pathways traded down 0.2%, reaching a price of $4.34.
• Analysts have varying price targets for the stock, with a consensus target price of $17.00 and ratings ranging from "hold" to "buy."

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) released its earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01), Zacks reports.

COMPASS Pathways Trading Down 3.2%

NASDAQ:CMPS traded down $0.15 during trading hours on Wednesday, reaching $4.34. The company's stock had a trading volume of 358,194 shares, compared to its average volume of 1,831,797. The firm has a market capitalization of $415.90 million, a price-to-earnings ratio of -2.37 and a beta of 2.17. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $8.54. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82. The firm has a 50-day simple moving average of $4.00 and a 200-day simple moving average of $3.82.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright lowered their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday. Evercore ISI reissued an "in-line" rating and issued a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Cantor Fitzgerald restated an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $15.00 target price on shares of COMPASS Pathways in a report on Friday, August 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $16.29.

Institutional Inflows and Outflows

An institutional investor recently raised its position in COMPASS Pathways stock. Royal Bank of Canada raised its holdings in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 49.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,446 shares of the company's stock after purchasing an additional 29,733 shares during the quarter. Royal Bank of Canada owned 0.10% of COMPASS Pathways worth $256,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.